Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy. Observational, Descriptive, Open-label, Multi-centric, Non-randomized Study

NCT02220114 is registered in ClinicalTrials.gov with Orphelia Pharma as lead sponsor.

NCT NCT02220114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02220114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy. Observational, Descriptive, Open-label, Multi-centric, Non-randomized Study
Lead sponsor
Orphelia Pharma
Phase
Not applicable
Overall status
Completed
Start date
May 31, 2014
Completion date
December 31, 2016
Enrollment
38 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

infantile spasms